摘要
目的:观察恩度联合EP方案治疗晚期小细胞肺癌的疗效及安全性。方法:47例符合入组条件的晚期小细胞肺癌患者随机分为2组:对照组(25例)采用EP方案;实验组(22例)在对照组的基础上于每周期化疗第1-14天给予恩度15mg/d,21d为1个周期,每2周期评价疗效。观察两组患者的毒副反应、客观缓解率、无进展生存时间以及总生存时间的差异。结果:对照组客观缓解率40%,实验组缓解率为68%,中位无进展时间分别为6.4个月和5.5个月,中位生存期分别为10.9个月和10个月,差异有统计学意义(P<0.05)。两组不良反应发生率无明显差别(P>0.05)。结论:EP化疗联合恩度可提高小细胞肺癌患者近期疗效及远期生存,且不良反应小,安全性好。
Objective： To analyze the effect and safety of human ecdostatin combined with EP（etoposide and cisplatin） regimen in the treatment of small cell lung cancer.Methods： Forty-seven patients with small cell lung cancer were randomly divided into EP treatment group（control） and combined treatment group.The control group received EP treatment only,while the combined treatment group additionally received 15 mg/d human endostatin treatment during the first 14 days on each chemotherapy cycle（21 days）.Two cycles later,the side effect and recent outcomes including the response rate（RR）,median progression-free survival（MPFS）,and median overall survival（MOS） between the two groups compared.Results： The RR of combined group and control group was 68% and 40% respectively,MPFS was 6.4 months and 5.5 months respectively,and MOS was 10.9 months and 10 months respectively,with significant difference between the two groups（all P0.05）.Adverse reactions were of no significant difference between the two groups（P0.05）.Conclusion： Human endostatin combined with EP regimen could improve the efficacy and long-term survival with little side effects in small cell lung cancer.
出处
《武汉大学学报（医学版）》
CAS
北大核心
2011年第6期846-848,共3页
Medical Journal of Wuhan University
关键词
小细胞肺癌
恩度
顺铂
依托泊甙
Small Cell Lung Cancer
Endostar
Cisplatin
Etoposide
